Is There A Point To Subgroup Analyses Of STABILITY?
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Co-chair of the failed study says secondary endpoints adding revascularization and unstable angina to the hard MACE primary endpoint show “hypothesis-generating” findings, but discussant Kastelein questions the prospects for any more trials to test those hypotheses.
You may also be interested in...
GSK’s Darapladib Poised To Become Latest Cardiovascular Outcomes Casualty
Company announces that Lp-PLA2 inhibitor darapladib fails Phase III STABILIITY outcomes study, the latest in a string of pharma CV failures.
Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116
As Merck’s 21-valent vaccine approaches its 17 June user fee goal, the US CDC’s vaccine committee is looking at new adult age-based recommendations and bracing for a full pipeline led by GSK’s 24-valent candidate.
US FDA Expects Joint AdComm Briefing Document, Oncology Chief Says
The combined format is the new default for briefing advisory committee members, US FDA Oncology Center of Excellence Director Pazdur declared.